Phase I Study of Anti-CD47 Monoclonal Antibody CC-90002 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

In this first clinical, phase I, dose-escalation and -expansion study, scientists evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.